Review



ventricular assist device system (hvad system  (HeartWare)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    HeartWare ventricular assist device system (hvad system
    Ventricular Assist Device System (Hvad System, supplied by HeartWare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/ventricular+assist+device/nct03681210-1-18-17
    Average 90 stars, based on 1 article reviews
    ventricular assist device system (hvad system - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: A study on the global patterns in the design and development of ventricular assist devices: a visualization approach
    Article Snippet: VAD, ventricular assist device; LVAD, left ventricular assist device; RVAD, right ventricular assist device; WoS, Web of Science; CFD, computational fluid dynamics; HVAD, HeartWare ventricular assist device.

    Article Title: Trans-atrial Inflow Cannula Configuration for Durable HeartWare Left Ventricular Assist Device in Hypertrophic Cardiomyopathy: A Case Series and a Word of Caution
    Article Snippet: Key: A – HeartWare ventricular assist device, B - outflow graft, C - native ascending aorta, D - driveline, E – towards ventricular apex .

    Article Title: Outcomes for Children With Congenital Heart Disease Undergoing Ventricular Assist Device Implantation: An ACTION Registry Analysis.
    Article Snippet: ISS Fro Su Ho Su Ca cin of de Th ins vis Ma BACKGROUND There are no contemporary reports that highlight the national outcomes for children with congenital heart disease (CHD) undergoing ventricular assist device (VAD) implantation.. OBJECTIVES This study sought to evaluate differences in VAD outcomes for children with CHD to those with non-CHD as well as those with univentricular CHD to those with biventricular CHD.. METHODS Data for CHD and non-CHD patients from the multicenter ACTION (Advanced Cardiac Therapies Improving Outcomes Network) undergoing VAD implantation from April 2018 to February 2023 were included.

    Article Title: Gastrointestinal Bleeding During Long-Term Left Ventricular Assist Device Support: External Validation of UTAH Bleeding Risk Score.
    Article Snippet: BTT—bridge to Transplant; BTC— bridge to Candidacy; CAD—coronary artery disease; CKD—chronic kidney disease; DT—destination therapy; HVAD—HeartWare Ventricular Assist Device; NYHA—New York Heart Association.

    Article Title: Predicting right ventricular failure after left ventricular assist device implant: A novel approach
    Article Snippet: Specifically, values were scaled to 8600 r.p.m. for HeartMate 2 (HM2), 2400 r.p.m. for HeartWare ventricular assist device (HVAD) and 4800 r.p.m. for HeartMate 3 (HM3), as per minimal nominal operating speeds dictated by the manufacturer.

    Article Title: Contemporary treatment of right ventricular failure
    Article Snippet: The HeartWare ventricular assist device is no longer available following its recall by the FDA in 2021 due to excess strokes and mortality concerns.

    Filtration:

    Article Title: Predicting right ventricular failure after left ventricular assist device implant: A novel approach.
    Article Snippet: .. Abbreviations: ACE, angiotensin-converting enzyme; AI, aortic insufficiency; anti-HTN, anti-hypertensive; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; BB, beta-blocker; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HVAD, HeartWare ventricular assist device; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LVIDD, left ventricular interior diastolic diameter; MR, mitral regurgitation; NHB, neurohormonal blocker; PASP, pulmonary artery systolic pressure; PV, pulmonary valve; RV, right ventricular; RVAD, right ventricular assist device; RVF, right ventricular failure; RVOT, right ventricular outflow tract; TTE, transthoracic echocardiogram; VTI, velocity time interval. aFive-point ordinal scores (0 = normal/none; 5 = severe) were recorded for AI, MR, tricuspid regurgitation, RV dilation and RV dysfunction. ..



    Similar Products

    86
    Abiomed Inc percutaneous left ventricular assist device
    Study flow diagram. Figure caption: Study flowchart outlining patient screening and enrollment for pulmonary WIA. Over a 12-month period, patients undergoing diagnostic RHC were screened. Ten control subjects were recruited from the post-heart transplant population and were required to be >6 months post-transplant, >18 years of age, and have normal pulmonary artery hemodynamics. Nineteen patients with CS were enrolled based on low cardiac index (CI <2.2 L/min/m²) and additional markers of hypoperfusion or organ dysfunction, with exclusion of those mechanically ventilated or recently resuscitated. CS subjects underwent implantation of either an IABP or Impella 5.5 device. All patients underwent simultaneous RHC and transthoracic Doppler TTE for WIA. Control subjects had a single recording, while CS patients were assessed pre- and post-MCS device implantation. A total of 29 subjects had complete paired pressure-flow datasets available for analysis. Abbreviations: ALT , Alanine Aminotransferase; CI , Cardiac Index; CS, Cardiogenic Shock; IABP , Intra-Aortic Balloon Pump; Impella 5.5, Percutaneous Left <t>Ventricular</t> Assist Device (Abiomed Impella 5.5); MCS , Mechanical Circulatory Support ; PA, Pulmonary Artery; RHC, Right Heart Catheterization; SBP, Systolic Blood Pressure; TTE , Transthoracic Echocardiography.
    Percutaneous Left Ventricular Assist Device, supplied by Abiomed Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/impella+rp+%D0%B8%D0%B7+%D0%B8%D0%B7%D0%B2%D0%B5%D1%81%D1%82%D0%BD%D1%8B%D1%85+%D0%BC%D0%B8%D0%BD%D0%B8%D0%B0%D1%82%D1%8E%D1%80%D0%BD%D1%8B%D1%85+%D0%BC%D0%BE%D0%B4%D0%B5%D0%BB%D0%B5%D0%B9+%D0%BE%D0%B4%D0%BD%D0%BE%D0%B9+%D1%83%D1%81%D1%82%D1%80%D0%BE%D0%B9%D1%81%D1%82%D0%B2+%D1%83%D1%81%D1%82%D1%80%D0%BE%D0%B9%D1%81%D1%82%D0%B2%D0%BE+%D1%88%D0%B8%D1%80%D0%BE%D0%BA%D0%BE+%D1%8F%D0%B2%D0%BB%D1%8F%D0%B5%D1%82%D1%81%D1%8F/pmc13053861-199-31-36
    Average 86 stars, based on 1 article reviews
    percutaneous left ventricular assist device - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    90
    HeartWare ventricular assist device system (hvad system
    Study flow diagram. Figure caption: Study flowchart outlining patient screening and enrollment for pulmonary WIA. Over a 12-month period, patients undergoing diagnostic RHC were screened. Ten control subjects were recruited from the post-heart transplant population and were required to be >6 months post-transplant, >18 years of age, and have normal pulmonary artery hemodynamics. Nineteen patients with CS were enrolled based on low cardiac index (CI <2.2 L/min/m²) and additional markers of hypoperfusion or organ dysfunction, with exclusion of those mechanically ventilated or recently resuscitated. CS subjects underwent implantation of either an IABP or Impella 5.5 device. All patients underwent simultaneous RHC and transthoracic Doppler TTE for WIA. Control subjects had a single recording, while CS patients were assessed pre- and post-MCS device implantation. A total of 29 subjects had complete paired pressure-flow datasets available for analysis. Abbreviations: ALT , Alanine Aminotransferase; CI , Cardiac Index; CS, Cardiogenic Shock; IABP , Intra-Aortic Balloon Pump; Impella 5.5, Percutaneous Left <t>Ventricular</t> Assist Device (Abiomed Impella 5.5); MCS , Mechanical Circulatory Support ; PA, Pulmonary Artery; RHC, Right Heart Catheterization; SBP, Systolic Blood Pressure; TTE , Transthoracic Echocardiography.
    Ventricular Assist Device System (Hvad System, supplied by HeartWare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/ventricular+assist+device/nct03681210-1-18-17
    Average 90 stars, based on 1 article reviews
    ventricular assist device system (hvad system - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    86
    Abbott Laboratories ventricular assist device
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Ventricular Assist Device, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/device+lvad/pmc12859017-83-25-21
    Average 86 stars, based on 1 article reviews
    ventricular assist device - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Baylor Scott & White left ventricular assist device
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Left Ventricular Assist Device, supplied by Baylor Scott & White, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/assist+device+left+ventricular/pm41350842-14-35-8
    Average 86 stars, based on 1 article reviews
    left ventricular assist device - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Abbott Laboratories heartmate 3 left ventricular assist device lvad
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Heartmate 3 Left Ventricular Assist Device Lvad, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/3+heartmate/sec_filing____1800_slash_000110465921025751_slash_abt___20201231x10k-1005-19-18
    Average 86 stars, based on 1 article reviews
    heartmate 3 left ventricular assist device lvad - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    90
    HeartWare durable continuous flow left ventricular assist devices
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Durable Continuous Flow Left Ventricular Assist Devices, supplied by HeartWare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/continuous+flow+ventricular+assist+device++hvad++pump/pmc12166462-166-20-26
    Average 90 stars, based on 1 article reviews
    durable continuous flow left ventricular assist devices - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    HeartWare ventricular assist device
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Ventricular Assist Device, supplied by HeartWare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/ventricular+assist+device/pmc12134536-137-6-3
    Average 90 stars, based on 1 article reviews
    ventricular assist device - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Innovative Therapies ventricular assist devices (vads)
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Ventricular Assist Devices (Vads), supplied by Innovative Therapies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/ventricular+assist+devices++vads+/pmc12268090-16-25-16
    Average 90 stars, based on 1 article reviews
    ventricular assist devices (vads) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Takeda left ventricular assist devices
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Left Ventricular Assist Devices, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/left+ventricular+assist+devices/pm40650852-254-21-8
    Average 90 stars, based on 1 article reviews
    left ventricular assist devices - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Abiomed Inc percutaneous left ventricular assist device impella cp
    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace <t>ventricular</t> function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.
    Percutaneous Left Ventricular Assist Device Impella Cp, supplied by Abiomed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ventricular+assist+device/percutaneous+left+ventricular+assist+device+impella/pm40645687-35-5-8
    Average 90 stars, based on 1 article reviews
    percutaneous left ventricular assist device impella cp - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Study flow diagram. Figure caption: Study flowchart outlining patient screening and enrollment for pulmonary WIA. Over a 12-month period, patients undergoing diagnostic RHC were screened. Ten control subjects were recruited from the post-heart transplant population and were required to be >6 months post-transplant, >18 years of age, and have normal pulmonary artery hemodynamics. Nineteen patients with CS were enrolled based on low cardiac index (CI <2.2 L/min/m²) and additional markers of hypoperfusion or organ dysfunction, with exclusion of those mechanically ventilated or recently resuscitated. CS subjects underwent implantation of either an IABP or Impella 5.5 device. All patients underwent simultaneous RHC and transthoracic Doppler TTE for WIA. Control subjects had a single recording, while CS patients were assessed pre- and post-MCS device implantation. A total of 29 subjects had complete paired pressure-flow datasets available for analysis. Abbreviations: ALT , Alanine Aminotransferase; CI , Cardiac Index; CS, Cardiogenic Shock; IABP , Intra-Aortic Balloon Pump; Impella 5.5, Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS , Mechanical Circulatory Support ; PA, Pulmonary Artery; RHC, Right Heart Catheterization; SBP, Systolic Blood Pressure; TTE , Transthoracic Echocardiography.

    Journal: JHLT Open

    Article Title: Pulmonary wave intensity analysis to assess ventriculo-arterial interactions in cardiogenic shock

    doi: 10.1016/j.jhlto.2026.100528

    Figure Lengend Snippet: Study flow diagram. Figure caption: Study flowchart outlining patient screening and enrollment for pulmonary WIA. Over a 12-month period, patients undergoing diagnostic RHC were screened. Ten control subjects were recruited from the post-heart transplant population and were required to be >6 months post-transplant, >18 years of age, and have normal pulmonary artery hemodynamics. Nineteen patients with CS were enrolled based on low cardiac index (CI <2.2 L/min/m²) and additional markers of hypoperfusion or organ dysfunction, with exclusion of those mechanically ventilated or recently resuscitated. CS subjects underwent implantation of either an IABP or Impella 5.5 device. All patients underwent simultaneous RHC and transthoracic Doppler TTE for WIA. Control subjects had a single recording, while CS patients were assessed pre- and post-MCS device implantation. A total of 29 subjects had complete paired pressure-flow datasets available for analysis. Abbreviations: ALT , Alanine Aminotransferase; CI , Cardiac Index; CS, Cardiogenic Shock; IABP , Intra-Aortic Balloon Pump; Impella 5.5, Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS , Mechanical Circulatory Support ; PA, Pulmonary Artery; RHC, Right Heart Catheterization; SBP, Systolic Blood Pressure; TTE , Transthoracic Echocardiography.

    Article Snippet: Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; NWI, net wave intensity; WIA , wave intensity analysis.

    Techniques: Diagnostic Assay, Control

    Representative pulmonary wave intensity analyses. Figure caption: Each panel displays wave intensity profiles derived from pressure-flow data over a single cardiac cycle, showing forward compression waves (FCW, blue), forward decompression waves (FDW, green), backward compression waves (BCW, red), and backward decompression waves (BDW, purple). The timing of peak BCW (red dotted line) and end of the cardiac cycle (black dotted line) are marked. All plots are normalized to the same x - (time) and y -(wave intensity) axes for comparison. 1a: pulmonary WIA during dobutamine infusion at 7.5 µg/kg/min in a patient with CS. This high-dose inotropic support is associated with increased forward wave intensity, a moderate increase in backward wave intensity, but no increase in reflected wave speed. 1b: pulmonary WIA during milrinone infusion at 0.375 µg/kg/min in a patient with CS. There is a minimal increase in forward-traveling wave intensity with salutatory effects on the backward-traveling wave intensity. There is a relative reduction in reflected wave speed, likely due to peripheral vasodilation. 1c: pulmonary WIA during sodium nitroprusside infusion at 1.25 µg/kg/min. There is minimal effect on forward or backward-traveling wave intensities. Reflected wave speed is increased consistent, likely due to the systemic vasodilatory action of sodium nitroprusside without direct inotropic effect. 1d: pulmonary WIA from a patient in CS prior to any treatment initiation. There are markedly reduced forward and backward wave intensities, with late return of the reflected wave, suggesting blunted wave generation and delayed reflection timing, likely due to CS with relative vasoplegia. 1e: pulmonary WIA from a patient in CS with IABP support-off and IABP support-on. IABP-on support is associated with increased forward-traveling wave intensities, as well as a delay to peak backward compression wave. 1f: pulmonary WIA from a patient in CS with Impella support off and Impella support on (performance level 8, flow 4.8 L/min). Impella-on support is also associated with increased forward-traveling wave intensities, with no significant effect on backward-traveling wave magnitudes or timing. Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , intra-aortic balloon pump; Impella, percutaneous left ventricular assist device (Abiomed Impella 5.5); MCS, mechanical circulatory support; WIA , wave intensity analysis.

    Journal: JHLT Open

    Article Title: Pulmonary wave intensity analysis to assess ventriculo-arterial interactions in cardiogenic shock

    doi: 10.1016/j.jhlto.2026.100528

    Figure Lengend Snippet: Representative pulmonary wave intensity analyses. Figure caption: Each panel displays wave intensity profiles derived from pressure-flow data over a single cardiac cycle, showing forward compression waves (FCW, blue), forward decompression waves (FDW, green), backward compression waves (BCW, red), and backward decompression waves (BDW, purple). The timing of peak BCW (red dotted line) and end of the cardiac cycle (black dotted line) are marked. All plots are normalized to the same x - (time) and y -(wave intensity) axes for comparison. 1a: pulmonary WIA during dobutamine infusion at 7.5 µg/kg/min in a patient with CS. This high-dose inotropic support is associated with increased forward wave intensity, a moderate increase in backward wave intensity, but no increase in reflected wave speed. 1b: pulmonary WIA during milrinone infusion at 0.375 µg/kg/min in a patient with CS. There is a minimal increase in forward-traveling wave intensity with salutatory effects on the backward-traveling wave intensity. There is a relative reduction in reflected wave speed, likely due to peripheral vasodilation. 1c: pulmonary WIA during sodium nitroprusside infusion at 1.25 µg/kg/min. There is minimal effect on forward or backward-traveling wave intensities. Reflected wave speed is increased consistent, likely due to the systemic vasodilatory action of sodium nitroprusside without direct inotropic effect. 1d: pulmonary WIA from a patient in CS prior to any treatment initiation. There are markedly reduced forward and backward wave intensities, with late return of the reflected wave, suggesting blunted wave generation and delayed reflection timing, likely due to CS with relative vasoplegia. 1e: pulmonary WIA from a patient in CS with IABP support-off and IABP support-on. IABP-on support is associated with increased forward-traveling wave intensities, as well as a delay to peak backward compression wave. 1f: pulmonary WIA from a patient in CS with Impella support off and Impella support on (performance level 8, flow 4.8 L/min). Impella-on support is also associated with increased forward-traveling wave intensities, with no significant effect on backward-traveling wave magnitudes or timing. Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , intra-aortic balloon pump; Impella, percutaneous left ventricular assist device (Abiomed Impella 5.5); MCS, mechanical circulatory support; WIA , wave intensity analysis.

    Article Snippet: Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; NWI, net wave intensity; WIA , wave intensity analysis.

    Techniques: Derivative Assay, Comparison

    Box-and-Whisker plots. Figure caption: Box-and-whisker plots demonstrate forward compression wave (FCW), forward decompression wave (FDW), backward compression wave (BCW), backward decompression wave (BDW), time-to-peak BCW, reflection index (RI), net wave intensity (NWI), and wave speed in 3 groups: healthy controls (0), patients with cardiogenic shock (CS; 1), and those supported with mechanical circulatory support (MCS; 2) using either intra-aortic balloon pump (IABP) or Impella 5.5. Significant pairwise differences were observed between controls and CS for BDW ( p < 0.01) and wave speed ( p < 0.01), and between CS and MCS for time-to-peak BCW ( p = 0.048). Significant pairwise differences between controls and MCS subjects in FCW ( p = 0.02), FDW ( p < 0.01), BDW ( p < 0.01), and wave speed ( p = 0.03) were observed. Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; NWI, net wave intensity; WIA , wave intensity analysis.

    Journal: JHLT Open

    Article Title: Pulmonary wave intensity analysis to assess ventriculo-arterial interactions in cardiogenic shock

    doi: 10.1016/j.jhlto.2026.100528

    Figure Lengend Snippet: Box-and-Whisker plots. Figure caption: Box-and-whisker plots demonstrate forward compression wave (FCW), forward decompression wave (FDW), backward compression wave (BCW), backward decompression wave (BDW), time-to-peak BCW, reflection index (RI), net wave intensity (NWI), and wave speed in 3 groups: healthy controls (0), patients with cardiogenic shock (CS; 1), and those supported with mechanical circulatory support (MCS; 2) using either intra-aortic balloon pump (IABP) or Impella 5.5. Significant pairwise differences were observed between controls and CS for BDW ( p < 0.01) and wave speed ( p < 0.01), and between CS and MCS for time-to-peak BCW ( p = 0.048). Significant pairwise differences between controls and MCS subjects in FCW ( p = 0.02), FDW ( p < 0.01), BDW ( p < 0.01), and wave speed ( p = 0.03) were observed. Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; NWI, net wave intensity; WIA , wave intensity analysis.

    Article Snippet: Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; NWI, net wave intensity; WIA , wave intensity analysis.

    Techniques: Whisker Assay

    Spaghetti plots pre- and post- MCS intervention. 4 (top): Pre- and post-IABP support changes in wave intensity parameters among patients with CS. Forward wave magnitudes (FCW, FDW) increased in most patients, while backward wave magnitudes (BCW, BDW) remained largely unchanged, resulting in a consistent reduction in reflection index (RI). There was no significant change in time-to-peak BCW or wave speed, suggesting preserved timing and stiffness characteristics. A general upward shift in net wave intensity (NWI) was observed, indicating improved overall wave energy balance and potentially more favorable ventriculo-arterial coupling with IABP support. 4 (bottom): Pre- and post-Impella 5.5support changes in wave intensity parameters among patients with CS. Following Impella 5.5 insertion, FCW and FDW magnitudes increased in several patients, though a subset showed either no change or a decrease. BCW timing was consistently delayed post-support, indicating later arrival of reflected waves. Backward wave magnitudes (BDW and BCW) generally became less negative, reflecting a reduction in wave reflection severity, although exceptions were noted. These changes were associated with a notable increase in RI in most individuals. Net wave intensity shifted upward in some cases, but responses were heterogeneous. Wave speed showed no consistent pattern, with both increases and decreases observed across the cohort. Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; WIA , wave intensity analysis.

    Journal: JHLT Open

    Article Title: Pulmonary wave intensity analysis to assess ventriculo-arterial interactions in cardiogenic shock

    doi: 10.1016/j.jhlto.2026.100528

    Figure Lengend Snippet: Spaghetti plots pre- and post- MCS intervention. 4 (top): Pre- and post-IABP support changes in wave intensity parameters among patients with CS. Forward wave magnitudes (FCW, FDW) increased in most patients, while backward wave magnitudes (BCW, BDW) remained largely unchanged, resulting in a consistent reduction in reflection index (RI). There was no significant change in time-to-peak BCW or wave speed, suggesting preserved timing and stiffness characteristics. A general upward shift in net wave intensity (NWI) was observed, indicating improved overall wave energy balance and potentially more favorable ventriculo-arterial coupling with IABP support. 4 (bottom): Pre- and post-Impella 5.5support changes in wave intensity parameters among patients with CS. Following Impella 5.5 insertion, FCW and FDW magnitudes increased in several patients, though a subset showed either no change or a decrease. BCW timing was consistently delayed post-support, indicating later arrival of reflected waves. Backward wave magnitudes (BDW and BCW) generally became less negative, reflecting a reduction in wave reflection severity, although exceptions were noted. These changes were associated with a notable increase in RI in most individuals. Net wave intensity shifted upward in some cases, but responses were heterogeneous. Wave speed showed no consistent pattern, with both increases and decreases observed across the cohort. Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; WIA , wave intensity analysis.

    Article Snippet: Abbreviations: BCW, backward compression wave; BDW , backward decompression wave; CS , cardiogenic shock; FCW , forward compression wave; FDW , forward decompression wave; IABP , Intra-Aortic Balloon Pump; Impella , Percutaneous Left Ventricular Assist Device (Abiomed Impella 5.5); MCS, mechanical circulatory support; NWI, net wave intensity; WIA , wave intensity analysis.

    Techniques:

    A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace ventricular function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.

    Journal: NPJ Regenerative Medicine

    Article Title: Optimized biomechanical design of a tissue engineered pulsatile Fontan conduit

    doi: 10.1038/s41536-025-00450-x

    Figure Lengend Snippet: A Schema of a canonical pressure–volume (P–V) loop biomimicking the right ventricle, as well as associated states, that a cylindrical pulsatile conduit will need to assume to replace ventricular function. B Illustrative multiaxial loops generated by a pulsatile conduit, comprising P–V, axial force–length, and torque–twist. The P–V loop reflects hemodynamic performance, while the force–length and torque–twist loops reflect additional work done. The overall shape of a P–V loop is defined by prescribed values of pressures ( P 1 , P 2 , P 3 , and P 4 ) and volumes (EDV and ESV) that are defined by physiological requirements (SV and EF). By contrast, shapes of force–length and torque–twist loops can be controlled by design parameters to optimize the overall function of the conduit.

    Article Snippet: The maximal available space in the thoracic cavity is assumed to be up to ~2.5 cm in diameter based on the Abbott HeartMate 3 Left Ventricular Assist Device and up to ~6.0 cm in length (if tubular), based on the distance between the intrapericardial part of the IVC and the undersurface of the right pulmonary artery for 3-year-old children .

    Techniques: Generated

    Basic conduit parameters for spherical ( A ) and cylindrical ( B ) geometries are deemed admissible if within the gray regions of interest (ROI) for an illustrative value of stroke volume SV = 17 ml and a range of ejection fractions EF \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\in$$\end{document} ∈ [0.5,0.8]. The maximal available space in the thoracic cavity is assumed to be up to ~2.5 cm in diameter based on the Abbott HeartMate 3 Left Ventricular Assist Device and up to ~6.0 cm in length (if tubular), based on the distance between the intrapericardial part of the IVC and the undersurface of the right pulmonary artery for 3-year-old children . These representative dimensions are also consistent with current GoreTex Fontan conduits.

    Journal: NPJ Regenerative Medicine

    Article Title: Optimized biomechanical design of a tissue engineered pulsatile Fontan conduit

    doi: 10.1038/s41536-025-00450-x

    Figure Lengend Snippet: Basic conduit parameters for spherical ( A ) and cylindrical ( B ) geometries are deemed admissible if within the gray regions of interest (ROI) for an illustrative value of stroke volume SV = 17 ml and a range of ejection fractions EF \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\in$$\end{document} ∈ [0.5,0.8]. The maximal available space in the thoracic cavity is assumed to be up to ~2.5 cm in diameter based on the Abbott HeartMate 3 Left Ventricular Assist Device and up to ~6.0 cm in length (if tubular), based on the distance between the intrapericardial part of the IVC and the undersurface of the right pulmonary artery for 3-year-old children . These representative dimensions are also consistent with current GoreTex Fontan conduits.

    Article Snippet: The maximal available space in the thoracic cavity is assumed to be up to ~2.5 cm in diameter based on the Abbott HeartMate 3 Left Ventricular Assist Device and up to ~6.0 cm in length (if tubular), based on the distance between the intrapericardial part of the IVC and the undersurface of the right pulmonary artery for 3-year-old children .

    Techniques: